<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502394</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-111</org_study_id>
    <nct_id>NCT04502394</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with&#xD;
      acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic&#xD;
      Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An Open-label, Phase 1b/2 Study of KRT-232 in combination with acalabrutinib in Subjects with B-cell Non-Hodgkin Lymphoma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective Phase 1b:To determine the KRT-232 maximum tolerated dose/ maximum administered dose (MTD/MAD) and recommended Phase 2 Dose (RP2D) in combination with acalabrutinib in subjects with R/R DLBCL or R/R CLL</measure>
    <time_frame>56 Days</time_frame>
    <description>Endpoint/Outcome Measures: Dose-limiting toxicities will be used to establish the MTD/MAD of KRT-232 in combination with acalabrutinib. The Safety Review Committee will determine the RP2D based on safety data of the combination of KRT-232 and acalabrutinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective Phase 2: Cohort 1: To determine the complete response (CR)</measure>
    <time_frame>1 Year</time_frame>
    <description>Endpoint/Outcome Measures: Cohort 1: The proportion of subjects with CR as assessed by investigators per the Lugano Classification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective Phase 2: Cohort 2: To determine the rate of CR/complete remission with incomplete hematologic recovery (CRi) rate in R/R CLL</measure>
    <time_frame>1 Year</time_frame>
    <description>Endpoint/Outcome Measures: Cohort 2: The proportion of subjects with CR/CRi as assessed by investigators per iwCLL Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Secondary Objective: Pharmacokinetic (PK) profile</measure>
    <time_frame>Baseline, 1, 2, 4, 6 and 24 hours post dose on days 1 and 2 of cycle 1 (each cycle is 28 days); Baseline and 2 hours post dose on day 1 and 24 hours post dose on day 8 of cycle 2</time_frame>
    <description>Endpoint/Outcome Measures: Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameter from a single dose will be estimated maximum concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Secondary Objective: Pharmacokinetic (PK) profile</measure>
    <time_frame>Baseline, 1, 2, 4, 6 and 24 hours post dose on days 1 and 2 of cycle 1 (each cycle is 28 days); Baseline and 2 hours post dose on day 1 and 24 hours post dose on day 8 of cycle 2</time_frame>
    <description>Endpoint/Outcome Measures: Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameters from a single dose will be area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Secondary Objective: Pharmacokinetic (PK) profile</measure>
    <time_frame>Baseline, 1, 2, 4, 6 and 24 hours post dose on days 1 and 2 of cycle 1 (each cycle is 28 days); Baseline and 2 hours post dose on day 1 and 24 hours post dose on day 8 of cycle 2</time_frame>
    <description>Endpoint/Outcome Measures: Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameters from a single dose will be half-life (T1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Secondary Objective: Pharmacokinetic (PK) profile</measure>
    <time_frame>Baseline, 1, 2, 4, 6 and 24 hours post dose on days 1 and 2 of cycle 1 (each cycle is 28 days); Baseline and 2 hours post dose on day 1 and 24 hours post dose on day 8 of cycle 2</time_frame>
    <description>Endpoint/Outcome Measures: Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameter from a single dose will be apparent clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Secondary Objective: Pharmacokinetic (PK) profile</measure>
    <time_frame>Baseline, 1, 2, 4, 6 and 24 hours post dose on days 1 and 2 of cycle 1 (each cycle is 28 days); Baseline and 2 hours post dose on day 1 and 24 hours post dose on day 8 of cycle 2</time_frame>
    <description>Endpoint/Outcome Measures: Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameters from a single dose will be apparent volume of distribution using non-compartmental or compartmental PK methods with the software WinNonlin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Secondary Objective: Cohort 1 (R/R DLBCL): To determine the overall response rate (ORR) for R/R DLBCL subjects.</measure>
    <time_frame>2 Years</time_frame>
    <description>Endpoint/Outcome Measures: The proportion of subjects who achieve a partial response (PR) or better at any time point while on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Secondary Objective: Cohort 2 (R/R CLL): To determine the ORR for R/R CLL subjects</measure>
    <time_frame>2 Years</time_frame>
    <description>Endpoint/Outcome Measures: The proportion of subjects who achieve a PR or better at any time point while on study, as assessed by iwCLL Response Criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (R/R DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.&#xD;
Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (R/R CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.&#xD;
Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth</description>
    <arm_group_label>Cohort 1 (R/R DLBCL)</arm_group_label>
    <arm_group_label>Cohort 2 (R/R CLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>acalabrutinib is a BTK inhibitor anticancer drug taken by mouth</description>
    <arm_group_label>Cohort 1 (R/R DLBCL)</arm_group_label>
    <arm_group_label>Cohort 2 (R/R CLL)</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior&#xD;
             lines of treatment or 1 prior for patients who are ineligible for stem cell transplant&#xD;
&#xD;
          -  Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior&#xD;
             line of treatment&#xD;
&#xD;
          -  ECOG 0 to 2&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any MDM2 inhibitor&#xD;
&#xD;
          -  Prior treatment with any BTK inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Yee</last_name>
    <phone>650-839-7361</phone>
    <email>myee@kartosthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cance Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Hradec Kralove</name>
      <address>
        <city>Nový Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia/Espinho EPE</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>navtemadlin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acalabrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

